Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

CM Bagi, DF Gebhard, CJ Andresen - European journal of …, 2012 - journals.lww.com
Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …
被引用次数：26 相关文章

[引用][C] Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

CM BAGI, DF GEBHARD… - European journal of …, 2012 - pascal-francis.inist.fr
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models
of hepatocellular carcinoma CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

CM Bagi, DF Gebhard… - European journal of …, 2012 - pubmed.ncbi.nlm.nih.gov
Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.

CM Bagi, DF Gebhard, CJ Andresen - European Journal of …, 2012 - europepmc.org
Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

[引用][C] Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

CM BAGI, DF GEBHARD… - European journal of …, 2012 - Lippincott Williams & Wilkins